Argenx, Zai Lab Shares Rise After Positive Trial Results for Vyvgart Hytrulo
By Chris Wack
Argenx shares were up 25% to $474.87 in premarket trading after the company said it and Zai Lab saw positive topline results from their study evaluating Vyvgart Hytrulo, or efgartigimod alfa and hyaluronidase-qvfc, in adults with chronic inflammatory demyelinating polyneuropathy.
Zai Lab shares were up 10% to $30.49 in premarket trading.
The companies said the study met its primary endpoint, demonstrating a significantly lower risk of relapse with Vyvgart Hytrulo compared with placebo.
The study showed that the safety and tolerability profile was consistent with confirmed safety profile of Vyvgart, and 91% of eligible patients continued to the next phase of the open-label extension study.
The most frequent treatment-related adverse event was injection site reactions, which occurred in a lower percentage of patients than previous Vyvgart Hytrulo trials. All injection site reactions were mild to moderate and resolved over time.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
July 17, 2023 06:55 ET (10:55 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits
-
Novo Nordisk Earnings: Raised Fair Value Estimate Still a Contrast to Market Overenthusiasm
-
After Earnings, Is Verizon Stock a Buy, a Sell, or Fairly Valued?
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
How to Invest Like Warren Buffett
-
Cognizant Earnings: Improved Profitability Buttresses Results as Customer Spending Remains Muted
-
10 Top-Performing Dividend Stocks of the Month